SELLAS to present Phase 2 SLS009 data at ASH meeting in December
Tweet Send to a Friend
SELLAS Life Sciences Group (NASDAQ: SLS) announced it will present Phase 2 clinical data for SLS009 (tambiciclib) at the 68th ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




